Explore the Agenda
7:00 am Check-In & Coffee
7:50 am Chair’s Opening Remarks
A Booming Radiopharmaceutical Landscape: Evaluating the Progress of TRPs in Europe & Beyond
8:00 am Radioligand Therapy: Successes & Future Challenges
Radiopharmaceuticals are on the rise worldwide. Join key players to explore how Europe is driving progress in this exciting field – and what it means for the future of cancer care around the world.
- Demonstrating significant progression-free survival benefits for mCRPC patients treated with Pluvicto
- The success of Pluvicto in improving progression-free survival compared to standard care
- New challenges and opportunities in RLT: new targets, combinations
8:30 am An Update on ProstACT Global: Comparing Standard of Care With or Without 177Lu-DOTA-Rosopatamab
- Evaluating the impact of adding 177Lu-DOTA-Rosopatamab to standard care in PSMA-positive mCRPC
- Assessing the safety and effectiveness of 177Lu-DOTA-Rosopatamab with androgen inhibitors or taxanes
- Exploring new therapeutic strategies for advanced prostate cancer using 177Lu-DOTA-Rosopatamab
9:00 am Radiopharmaceutical Clinical Trials: Practical Implementation & Key Challenges
- Lessons learned from delivering pivotal radioligand trials
- Practical realities of radioactive drug management, imaging, and dosimetry
- Operational recommendations for site logistics, enrolment, and beyond
9:30 am Delivering on the Promise of Targeted Radiopharmaceuticals: Emerging Therapy & Innovation Platforms
- Developing first-in-class versus best-in-class radiopharmaceuticals
- Emerging clinical data from best-in-class approaches
- Validation of preclinical platforms to deliver blockbuster after blockbuster
10:00 am Morning Break & Speed Networking
Discovery & Preclinical Track
Radioisotope Selection: Exploring Alpha VS Beta Emitters
11:00 am Roundtable Discussion: Elucidating Radiobiological Mechanisms of Cytotoxicity & Immune Modulation to Inform Selection of Optimal Radiopharmaceutical Targets
Director - Oncology Safety Sciences, AstraZeneca
- Investigating the cellular and molecular mechanisms underlying radiopharmaceutical-induced cell death to optimise therapeutic outcomes
- Exploring how radiopharmaceuticals interact with the immune system to enhance anti-tumour immunity and reduce resistance
- Leveraging insights from radiobiology and immune modulation to identify and select optimal radiopharmaceutical targets for improved tumour control and reduced toxicity
11:30 am Do You Know Where Your Daughters Are? I Know Where Are Mine
Chief Vision Officer, BIOEMTECH Laboratories
- Challenges in imaging alpha emitters, particularly Ac-225, at both preclinical and clinical levels
- Importance of monitoring the biodistribution of Ac-225 daughters for accurate dose calculations
- In vivo imaging and ex vivo biodistribution data, showing the feasibility of following Ac-225 daughters over time
12:00 pm Choosing the Right Radiation Modality: Radiobiological Insights into Alpha, Beta & External Beam Radiation
Associate Professor, Radiobiology of Radionuclide Therapy, Erasmus MC Cancer Institute
- Exploring key radiobiological parameters that influence treatment response
- Comparing how alpha-emitters, beta-emitters, and external beam radiation differ in physical properties and biological effects
- Demonstrating how these differences impact therapeutic efficacy and guide personalized radionuclide selection
Translational & Clinical Development Track
CMC & Sourcing Track
12:30 pm Lunch
Discovery & Preclinical Track
Exploring Targets Beyond PSMA: Ongoing Discovery to Find Real Hits on Novel Targets
1:30 pm Characterising Key Attributes of an Ideal Radiopharmaceutical Target for Alignment with Radiotherapeutic Properties
Chief Executive Officer & Chief Marketing Officer, Coretag
- Evaluating receptor expression profiles and proximity to radiosensitive tissues
- Defining target selection criteria based on emission characteristics of alpha versus. beta emitters
- Exploring strategies for stromal and internalising target engagement, including FAP-directed approaches
2:00 pm Session Reserved for Navigo Proteins
Head of Business Development, Navigo Proteins GmbH
2:10 pm Towards Optimising Tumour Retention of FAP-Targeting Theranostics
CEO, ActiThera
- Discussing the promise of FAP as a target for the imaging and therapy of various solid tumours
- Summarising approaches used in the FAP field to optimise tumour AUC
- Exploring insights into Actithera’s approaches and molecules
Translational & Clinical Development Track
CMC & Sourcing Track
2:40 pm Afternoon Break & Poster Presentation Session
Investigating a Well-Rounded Approach to Isotope Selection from Discovery to Manufacturing
3:30 pm Right Molecule, Right Isotope, Right Target: Engineering Smarter Radioligands
- Importance of isotope and chelator choice for binding, stability, and pharmacokinetics
- AI-driven in silico screening of isotopes, chelators, linkers and ligands
- Matching isotopes and chelators to radioligands PK, efficacy, and safety profiles
4:00 pm Optimising Isotope Selection for Scalable Radiopharmaceutical Commercialisation
- Evaluating isotope availability, production capacity, and logistics for reliable clinical and commercial use
- Aligning isotope half-life, emission type, and energy with therapeutic goals and pharmacokinetics
- Addressing regulatory, technical, and cost considerations for efficient scale-up and market readiness
4:30 pm Exploring Strategies for Improved Global Radio-Isotope & Therapy Supply Chain Management
- Investigating current challenges and solutions in global actinium-225 production and distribution
- Emerging technologies and infrastructure for scalable, high-purity isotope generation
- Addressing regulatory, logistical, and economic barriers to support widespread adoption of actinium-based therapies